154 related articles for article (PubMed ID: 15196814)
1. HIV hollow fiber SCID model for antiviral therapy comparison with SCID/hu model.
Taggart BR; Harrington P; Hollingshead M
Antiviral Res; 2004 Jul; 63(1):1-6. PubMed ID: 15196814
[TBL] [Abstract][Full Text] [Related]
2. SCID-hu mice: a model for studying disseminated HIV infection.
Goldstein H; Pettoello-Mantovani M; Katopodis NF; Kim A; Yurasov S; Kollmann TR
Semin Immunol; 1996 Aug; 8(4):223-31. PubMed ID: 8883145
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-4-transgenic hu-PBL-SCID mice: a model for the screening of antiviral drugs and immunotherapeutic agents against X4 HIV-1 viruses.
Okuma K; Tanaka R; Ogura T; Ito M; Kumakura S; Yanaka M; Nishizawa M; Sugiura W; Yamamoto N; Tanaka Y
J Infect Dis; 2008 Jan; 197(1):134-41. PubMed ID: 18171296
[TBL] [Abstract][Full Text] [Related]
4. Gene therapy using a simian virus 40-derived vector inhibits the development of in vivo human immunodeficiency virus type 1 infection of severe combined immunodeficiency mice implanted with human fetal thymic and liver tissue.
Goldstein H; Pettoello-Mantovani M; Anderson CM; Cordelier P; Pomerantz RJ; Strayer DS
J Infect Dis; 2002 May; 185(10):1425-30. PubMed ID: 11992277
[TBL] [Abstract][Full Text] [Related]
5. Validation of the SCID-hu Thy/Liv mouse model with four classes of licensed antiretrovirals.
Stoddart CA; Bales CA; Bare JC; Chkhenkeli G; Galkina SA; Kinkade AN; Moreno ME; Rivera JM; Ronquillo RE; Sloan B; Black PL
PLoS One; 2007 Aug; 2(7):e655. PubMed ID: 17668043
[TBL] [Abstract][Full Text] [Related]
6. SCID-Hu mouse as a model for human lung HIV-1 infection.
Cesbron JY; Agut H; Gosselin B; Candotti D; Raphaël M; Puech F; Grandadam M; Debré P; Capron A; Autran B
C R Acad Sci III; 1994 Jul; 317(7):669-74. PubMed ID: 7882151
[TBL] [Abstract][Full Text] [Related]
7. Pertussis toxin B-oligomer inhibits HIV infection and replication in hu-PBL-SCID mice.
Lapenta C; Spada M; Santini SM; Racca S; Dorigatti F; Poli G; Belardelli F; Alfano M
Int Immunol; 2005 Apr; 17(4):469-75. PubMed ID: 15746245
[TBL] [Abstract][Full Text] [Related]
8. The SCID-hu mouse as a model for HIV-1 infection.
Aldrovandi GM; Feuer G; Gao L; Jamieson B; Kristeva M; Chen IS; Zack JA
Nature; 1993 Jun; 363(6431):732-6. PubMed ID: 8515816
[TBL] [Abstract][Full Text] [Related]
9. Saquinavir-mediated inhibition of human immunodeficiency virus (HIV) infection in SCID mice implanted with human fetal thymus and liver tissue: an in vivo model for evaluating the effect of drug therapy on HIV infection in lymphoid tissues.
Pettoello-Mantovani M; Kollmann TR; Raker C; Kim A; Yurasov S; Tudor R; Wiltshire H; Goldstein H
Antimicrob Agents Chemother; 1997 Sep; 41(9):1880-7. PubMed ID: 9303378
[TBL] [Abstract][Full Text] [Related]
10. The SCID-hu mouse: an in-vivo model for HIV-1 pathogenesis and stem cell gene therapy for AIDS.
Jamieson BD; Aldrovandi GM; Zack JA
Semin Immunol; 1996 Aug; 8(4):215-21. PubMed ID: 8883144
[TBL] [Abstract][Full Text] [Related]
11. Development and applications of the SCID-hu mouse model.
McCune JM
Semin Immunol; 1996 Aug; 8(4):187-96. PubMed ID: 8883141
[TBL] [Abstract][Full Text] [Related]
12. Chimeric toxins targeted to the human immunodeficiency virus type 1 envelope glycoprotein augment the in vivo activity of combination antiretroviral therapy in thy/liv-SCID-Hu mice.
Goldstein H; Pettoello-Mantovani M; Bera TK; Pastan IH; Berger EA
J Infect Dis; 2000 Mar; 181(3):921-6. PubMed ID: 10720513
[TBL] [Abstract][Full Text] [Related]
13. Defining antibody protection against HIV-1 transmission in Hu-PBL-SCID mice.
Koup RA; Safrit JT; Weir R; Gauduin MC
Semin Immunol; 1996 Aug; 8(4):263-8. PubMed ID: 8883150
[TBL] [Abstract][Full Text] [Related]
14. Development of a novel transgenic mouse/SCID-hu mouse system to characterize the in vivo behavior of reservoirs of human immunodeficiency virus type 1-infected cells.
Wang EJ; Pettoello-Mantovani M; Anderson CM; Osiecki K; Moskowitz D; Goldstein H
J Infect Dis; 2002 Nov; 186(10):1412-21. PubMed ID: 12404156
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of antiretrovirals in animal models of HIV infection.
Van Rompay KK
Antiviral Res; 2010 Jan; 85(1):159-75. PubMed ID: 19622373
[TBL] [Abstract][Full Text] [Related]
16. Development of a human thymic organ culture model for the study of HIV pathogenesis.
Bonyhadi ML; Su L; Auten J; McCune JM; Kaneshima H
AIDS Res Hum Retroviruses; 1995 Sep; 11(9):1073-80. PubMed ID: 8554904
[TBL] [Abstract][Full Text] [Related]
17. thy/liv-SCID-hu mice: a system for investigating the in vivo effects of multidrug therapy on plasma viremia and human immunodeficiency virus replication in lymphoid tissues.
Pettoello-Mantovani M; Kollmann TR; Katopodis NF; Raker C; Kim A; Yurasov S; Wiltshire H; Goldstein H
J Infect Dis; 1998 Feb; 177(2):337-46. PubMed ID: 9466519
[TBL] [Abstract][Full Text] [Related]
18. Potent anti-R5 human immunodeficiency virus type 1 effects of a CCR5 antagonist, AK602/ONO4128/GW873140, in a novel human peripheral blood mononuclear cell nonobese diabetic-SCID, interleukin-2 receptor gamma-chain-knocked-out AIDS mouse model.
Nakata H; Maeda K; Miyakawa T; Shibayama S; Matsuo M; Takaoka Y; Ito M; Koyanagi Y; Mitsuya H
J Virol; 2005 Feb; 79(4):2087-96. PubMed ID: 15681411
[TBL] [Abstract][Full Text] [Related]
19. Use of standardized SCID-hu Thy/Liv mouse model for preclinical efficacy testing of anti-human immunodeficiency virus type 1 compounds.
Rabin L; Hincenbergs M; Moreno MB; Warren S; Linquist V; Datema R; Charpiot B; Seifert J; Kaneshima H; McCune JM
Antimicrob Agents Chemother; 1996 Mar; 40(3):755-62. PubMed ID: 8851606
[TBL] [Abstract][Full Text] [Related]
20. In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques.
Ambrose Z; Boltz V; Palmer S; Coffin JM; Hughes SH; Kewalramani VN
J Virol; 2004 Dec; 78(24):13553-61. PubMed ID: 15564466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
